BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 18753823)

  • 41. 18F-FDG PET for evaluation of the treatment response in patients with gastrointestinal tract lymphomas.
    Kumar R; Xiu Y; Potenta S; Mavi A; Zhuang H; Yu JQ; Dhurairaj T; Dadparvar S; Alavi A
    J Nucl Med; 2004 Nov; 45(11):1796-803. PubMed ID: 15534046
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Positron emission tomography/computed tomography in the management of Hodgkin's disease and non-Hodgkin's lymphoma.
    Rodríguez-Vigil B; Gómez-León N; Pinilla I; Hernández-Maraver D; Coya J; Martín-Curto L
    Curr Probl Diagn Radiol; 2006; 35(4):151-63. PubMed ID: 16814002
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin's lymphoma by 18F-fluorodeoxyglucose positron emission tomography.
    Bodet-Milin C; Kraeber-Bodéré F; Dupas B; Morschhauser F; Gastinne T; Le Gouill S; Campion L; Harousseau JL; Wegener WA; Goldenberg DM; Huglo D
    Haematologica; 2008 Mar; 93(3):390-7. PubMed ID: 18268287
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Comparison between conventional imaging methods and positron emission tomography in the treatment of Hodgkin's lymphoma].
    Móciková H; Marková J; Bĕlohlávek O; Cáp F; Cermák F; Feltl D; Kozák T
    Cas Lek Cesk; 2004; 143(7):476-9; discussion 479-80. PubMed ID: 15373291
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Whole body positron emission tomography in the treatment of Hodgkin disease.
    Hueltenschmidt B; Sautter-Bihl ML; Lang O; Maul FD; Fischer J; Mergenthaler HG; Bihl H
    Cancer; 2001 Jan; 91(2):302-10. PubMed ID: 11180075
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Staging, response to therapy, and restaging of lymphomas with 18F-FDG PET.
    Altamirano J; Esparza JR; de la Garza Salazar J; Calvo PS; Vera SR; Chalapud Revelo JR; Estrada G
    Arch Med Res; 2008 Jan; 39(1):69-77. PubMed ID: 18067998
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Comparison of findings with 18-FDG PET and CT in pretherapeutic staging of malignant lymphoma].
    Thill R; Neuerburg J; Fabry U; Cremerius U; Wagenknecht G; Hellwig D; Osieka R; Günther R; Büll U
    Nuklearmedizin; 1997 Oct; 36(7):234-9. PubMed ID: 9441282
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Atypical thoracic and supraclavicular FDG-uptake in patients with Hodgkin's and non-Hodgkin's lymphoma.
    Döbert N; Menzel C; Hamscho N; Wördehoff W; Kranert WT; Grünwald F
    Q J Nucl Med Mol Imaging; 2004 Mar; 48(1):33-8. PubMed ID: 15195002
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma.
    Hoh CK; Glaspy J; Rosen P; Dahlbom M; Lee SJ; Kunkel L; Hawkin RA; Maddahi J; Phelps ME
    J Nucl Med; 1997 Mar; 38(3):343-8. PubMed ID: 9074514
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer.
    Crippa F; Agresti R; Seregni E; Greco M; Pascali C; Bogni A; Chiesa C; De Sanctis V; Delledonne V; Salvadori B; Leutner M; Bombardieri E
    J Nucl Med; 1998 Jan; 39(1):4-8. PubMed ID: 9443729
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Positron emission tomography using F-18 fluorodeoxyglucose pre- and post-autologous stem cell transplant in non-Hodgkin's lymphoma.
    Johnston PB; Wiseman GA; Micallef IN
    Bone Marrow Transplant; 2008 Jun; 41(11):919-25. PubMed ID: 18391991
    [TBL] [Abstract][Full Text] [Related]  

  • 52. PET/CT in lymphoma: prospective study of enhanced full-dose PET/CT versus unenhanced low-dose PET/CT.
    Rodríguez-Vigil B; Gómez-León N; Pinilla I; Hernández-Maraver D; Coya J; Martín-Curto L; Madero R
    J Nucl Med; 2006 Oct; 47(10):1643-8. PubMed ID: 17015900
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluation of head and neck cancer with 18F-FDG PET: a comparison with conventional methods.
    Kresnik E; Mikosch P; Gallowitsch HJ; Kogler D; Wiesser S; Heinisch M; Unterweger O; Raunik W; Kumnig G; Gomez I; Grünbacher G; Lind P
    Eur J Nucl Med; 2001 Jul; 28(7):816-21. PubMed ID: 11504077
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Clinical value of FDG PET for therapy monitoring of malignant lymphoma--results of a retrospective study in 72 patients].
    Cremerius U; Fabry U; Kröll U; Zimny M; Neuerburg J; Osieka R; Büll U
    Nuklearmedizin; 1999; 38(1):24-30. PubMed ID: 9987778
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Utility of FDG-PET/CT in follow-up of children treated for Hodgkin and non-Hodgkin lymphoma.
    Rhodes MM; Delbeke D; Whitlock JA; Martin W; Kuttesch JF; Frangoul HA; Shankar S
    J Pediatr Hematol Oncol; 2006 May; 28(5):300-6. PubMed ID: 16772881
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease.
    Jerusalem G; Beguin Y; Fassotte MF; Najjar F; Paulus P; Rigo P; Fillet G
    Haematologica; 2001 Mar; 86(3):266-73. PubMed ID: 11255273
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study.
    Gallamini A; Hutchings M; Rigacci L; Specht L; Merli F; Hansen M; Patti C; Loft A; Di Raimondo F; D'Amore F; Biggi A; Vitolo U; Stelitano C; Sancetta R; Trentin L; Luminari S; Iannitto E; Viviani S; Pierri I; Levis A
    J Clin Oncol; 2007 Aug; 25(24):3746-52. PubMed ID: 17646666
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The role of 18F-FDG PET and 18F-FDG PET/CT in the evaluation of pediatric Hodgkin's lymphoma and non-Hodgkin's lymphoma.
    Qiu L; Chen Y; Wu J
    Hell J Nucl Med; 2013; 16(3):230-6. PubMed ID: 24137577
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual Hodgkin's disease mediastinal masses.
    Panizo C; Pérez-Salazar M; Bendandi M; Rodríguez-Calvillo M; Boán JF; García-Velloso MJ; Richter J; Rocha E
    Leuk Lymphoma; 2004 Sep; 45(9):1829-33. PubMed ID: 15223643
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma.
    Zinzani PL; Tani M; Trisolini R; Fanti S; Stefoni V; Alifano M; Castellucci P; Musuraca G; Dalpiaz G; Alinari L; Marchi E; Fina M; Pellegrini C; Farsad M; Cancellieri A; Busca A; Canini R; Pileri S; Baccarani M; Boaron M
    Haematologica; 2007 Jun; 92(6):771-7. PubMed ID: 17550849
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.